FY2024 EPS Estimates for Femasys Lowered by HC Wainwright

Femasys Inc. (NASDAQ:FEMY) – Analysts at HC Wainwright dropped their FY2024 earnings per share estimates for shares of Femasys in a research note issued to investors on Tuesday, February 11th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($0.87) for the year, down from their prior forecast of ($0.84). HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.84) per share. HC Wainwright also issued estimates for Femasys’ Q4 2024 earnings at ($0.25) EPS, FY2025 earnings at ($0.68) EPS, FY2026 earnings at ($0.39) EPS, FY2027 earnings at ($0.32) EPS and FY2028 earnings at ($0.19) EPS.

Femasys (NASDAQ:FEMY) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. The company had revenue of $0.55 million during the quarter, compared to analyst estimates of $0.40 million.

Separately, Chardan Capital decreased their price objective on Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th.

Femasys Trading Up 4.5 %

NASDAQ:FEMY opened at $1.38 on Friday. The company has a current ratio of 3.94, a quick ratio of 3.26 and a debt-to-equity ratio of 0.86. Femasys has a 1-year low of $0.86 and a 1-year high of $2.40. The stock has a fifty day simple moving average of $1.14 and a 200 day simple moving average of $1.12.

Institutional Investors Weigh In On Femasys

Several institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its holdings in shares of Femasys by 4.7% during the 4th quarter. Geode Capital Management LLC now owns 216,164 shares of the company’s stock valued at $238,000 after buying an additional 9,681 shares during the last quarter. XTX Topco Ltd lifted its holdings in shares of Femasys by 123.9% during the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after buying an additional 18,004 shares during the last quarter. Aljian Capital Management LLC acquired a new stake in shares of Femasys during the 3rd quarter valued at about $27,000. Finally, Virtu Financial LLC acquired a new stake in shares of Femasys during the 4th quarter valued at about $25,000. 65.27% of the stock is currently owned by institutional investors and hedge funds.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.